Search clinical trials for: BIIL 284 BS boli

Total 67 results

Boehringer Ingelheim

Completed

Relative Bioavailability, Pharmacokinetics, Safety and Tolerability of BIIL 284 BS in Healthy Volunteers

Healthy
Boehringer Ingelheim

Completed

Relative Bioavailability, Pharmacokinetics, Safety and Tolerability of BIIL 284 BS in Healthy Volunteers

Healthy
Boehringer Ingelheim

Completed

Efficacy and Safety of BIIL 284 BS in Adult Patients With Active Rheumatoid Arthritis

Arthritis, Rheumatoid
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of Increasing Doses of BIIL 284 BS in Adult and Pediatric Cystic Fibrosis (CF) Patients

Cystic Fibrosis
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of BIIL 284 BS in Adult and Pediatric Cystic Fibrosis (CF) Patients

Cystic Fibrosis
Boehringer Ingelheim

Completed

Effect of Treatment With BIIL 284 BS on Exercise Endurance in Patients With Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive
Boehringer Ingelheim

Completed

Relative Bioavailability, Safety and Tolerability of Two Tablet Formulations of BIIL 284 BS

Healthy
Boehringer Ingelheim

Completed

Pharmacokinetics, Safety and Tolerability of BIIL 284 BS in Patients With Hepatic Impairment in Comparison to Healthy Volunteers

Hepatic Insufficiency
Boehringer Ingelheim

Completed

The Effect of BIIL 284 BS on Induced-sputum Variables in Patients With Bronchial Asthma

Asthma
Boehringer Ingelheim

Completed

Effect of BIIL 284 BS on Patients With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive
Boehringer Ingelheim

Completed

Pharmacokinetics, Safety and Efficacy of BIIL 284 BS in Patients With Rheumatoid Arthritis (RA)

Arthritis, Rheumatoid
Boehringer Ingelheim

Completed

Study to Investigate the Safety, Tolerability, Biological Effects and Preliminary Pharmacokinetics of Increasing Doses of BIIL 284 BS in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Terminated

Efficacy and Safety of 24 Weeks of Oral Treatment With BIIL 284 BS in Adult and Pediatric Patients

Cystic Fibrosis

United States
Boehringer Ingelheim

Completed

Metabolism and Pharmacokinetics of [14C]-BIIL 284 BS in Healthy Volunteers

Healthy
Boehringer Ingelheim

Completed

Effect of Different Food Compositions on Bioavailability of BIIL 284 BS in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Safety, Tolerability, Biological Effects and Pharmacokinetics of BIIL 284 BS in Healthy Males

Healthy
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of Increasing Repeated Doses of BIIF 1149 BS in Healthy Male Volunteers

Healthy
Chroma Therapeutics

Terminated

Clinical Trial of the Safety and Effectiveness of CHR-2797 With Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

United States
Boehringer Ingelheim

Completed

Study to Evaluate the Effect of Multiple Doses of BIIL 284 BS on the Pharmacokinetics of Prednisone in Healthy Male Subjects

Healthy
Wyeth is now a wholly owned subsidiary of Pfizer

Terminated

Study Evaluating rhIL-11 in Left-Sided Ulcerative Colitis

Ulcerative Colitis | Inflammatory Bowel Disease
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacodynamics After Oral Administration of BIIF 1149 BS in Healthy Male Volunteers

Healthy
HonorHealth Research Institute
Neolight

Completed

Comparison of Phototherapy Using Neolight Skylife Versus Standardized Phototherapy for Hyperbilirubinemia in Newborns

Neonatal Hyperbilirubinemia | Jaundice, Neonatal | Neonatal Disorder

United States
Amy Liew

Completed

Speech Performance of Rugby Players When Using Different Types of Mouthguard

Speech

Malaysia
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacodynamics of BIIF 1149 BS in Healthy Young Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Effect of BIIL 284 BS on the Pharmacokinetics of Theophylline in Healthy Male Volunteers

Healthy
Russell Swerdlow, MD
Ausio Pharmaceuticals, LLC

Completed

S-Equol in Alzheimer's Disease (SEAD) Trial (SEAD)

Alzheimer's Disease

United States
University of Rochester

Completed

Glycerin Suppositories to Reduce Jaundice in Premature Infants

Prematurity | Neonatal Hyperbilirubinemia | Idiopathic Hyperbilirubinemia

United States
Enzymotec
Biostime, Inc. (Guangzhou)

Completed

Effect of InFat™ Product on Stool Biochemistry and Stool Characteristics in Formula-fed Term Infants in China

Health Behavior | Personal Satisfaction

China
Washington University School of Medicine
Eunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaborators

Completed

Innovative Tools to Expand HIV Self-Testing (I-TEST)

Sexually Transmitted Diseases | HIV/AIDS

Nigeria
University of Aarhus

Unknown

Comparison of Double Pad Fiber Optic Device Versus Conventional Phototherapy

Neonatal Hyperbilirubinemia
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of BI 653048 BS H3PO4 Capsule Assessing Endotoxin-induced Inflammatory Response in Healthy Male Subjects

Healthy
Radboud University Medical Center
CoMentis

Completed

Anti-inflammatory Effects of GTS-21 After LPS

Sepsis | Endotoxemia | Vagal Activity

Netherlands
Boehringer Ingelheim

Completed

Study of Pharmacokinetic Interaction Between Combivir® (ZDV+3TC) and BILR 355 BS Plus Ritonavir in Healthy Subjects

Healthy
University of Southern California
National Cancer Institute (NCI); Amgen

Terminated

5-FU Based Maintenance Therapy in RAS Wild Type Metastatic Colorectal Cancer After Induction With FOLFOX Plus Panitumumab

Stage IV Colorectal Cancer AJCC v7 | Stage IVA Colorectal Cancer AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Colorectal Adenocarcinoma | RAS Wild Type | Stage III Colorectal Cancer AJCC v7 | Stage IIIA Colorectal Cancer AJCC v7 | Stage IIIB Colorectal Cancer AJCC v7 | Stage IIIC Colorectal Cancer...

United States
National Cancer Institute (NCI)

Completed

Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery (S1310)

Hilar Cholangiocarcinoma | Advanced Adult Hepatocellular Carcinoma | Localized Non-Resectable Adult Liver Carcinoma | Recurrent Adult Liver Carcinoma | Recurrent Gallbladder Carcinoma | Stage IV Distal Bile Duct Cancer | Unresectable Extrahepatic Bile Duct Carcinoma | Stage II Gallbladder Cancer | Stage... and other conditions

United States
National Cancer Institute (NCI)

Completed

Alisertib and Combination Chemotherapy in Treating Patients With Gastrointestinal Tumors

Malignant Digestive System Neoplasm

United States
National Cancer Institute (NCI)

Active, not recruiting

FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer

Metastatic Pancreatic Adenocarcinoma | Recurrent Pancreatic Carcinoma | Stage IV Pancreatic Cancer AJCC v6 and v7

United States
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Recruiting

Testing the Addition of Radiotherapy to the Usual Treatment (Chemotherapy) for Patients With Esophageal and Gastric Cancer That Has Spread to a Limited Number of Other Places in the Body

Clinical Stage IV Gastric Cancer AJCC v8 | Metastatic Gastric Adenocarcinoma | Clinical Stage IV Esophageal Adenocarcinoma AJCC v8 | Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8 | Clinical Stage IVA Gastric Cancer AJCC v8 | Clinical Stage IVB Esophageal Adenocarcinoma AJCC v8 | Clinical... and other conditions

United States
NRG Oncology
National Cancer Institute (NCI)

Active, not recruiting

Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery

Colon Adenocarcinoma | Stage IIA Colon Cancer AJCC v8

United States, Canada, Puerto Rico
Jonsson Comprehensive Cancer Center
Bristol-Myers Squibb; NovoCure Ltd.

Recruiting

Nivolumab in Combination With Chemotherapy Pre-Surgery in Treating Patients With Borderline Resectable Pancreatic Cancer

Borderline Resectable Pancreatic Adenocarcinoma | Resectable Pancreatic Ductal Adenocarcinoma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Terminated

FOLFIRI and Panitumumab in Treating Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer

Recurrent Colorectal Carcinoma | Stage IVA Colorectal Cancer | Stage IVB Colorectal Cancer

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing the Addition of an Anticancer Drug, BAY 1895344, to the Usual Chemotherapy With FOLFIRI in Advanced or Metastatic Cancers of the Stomach and Intestines

Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage IV Gastric Cancer AJCC v8 | Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 | Metastatic Gastroesophageal Junction Adenocarcinoma | Metastatic... and other conditions

United States
University of Nebraska
National Cancer Institute (NCI)

Terminated

Panitumumab, Combination Chemotherapy, & Radiation Therapy in Esophageal or Gastroesophageal Junction Cancer

Esophageal Adenocarcinoma | Adenocarcinoma of the Gastroesophageal Junction | Stage IIB Esophageal Cancer | Stage IIA Esophageal Cancer

United States
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Active, not recruiting

Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer

Metastatic Pancreatic Adenocarcinoma | Stage IV Pancreatic Cancer AJCC v6 and v7 | Stage IV Colorectal Cancer AJCC v7 | Stage IVA Colorectal Cancer AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Metastatic Gastroesophageal Junction Adenocarcinoma | Metastatic Colorectal Carcinoma | Metastatic Malignant... and other conditions

United States
University of Nebraska
National Cancer Institute (NCI)

Completed

Chemotherapy, Stereotactic Body Radiation Therapy & Nelfinavir Mesylate in Locally Advanced Pancreatic Cancer

Pancreatic Adenocarcinoma | Stage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage II Pancreatic Cancer | Stage I Pancreatic Cancer | Resectable Pancreatic Carcinoma | Stage IA Pancreatic Cancer | Stage IB Pancreatic Cancer

United States
Albert Einstein College of Medicine
National Cancer Institute (NCI)

Terminated

Gemcitabine Hydrochloride, and Radiation Therapy in Patients With Borderline Resectable Pancreatic Cancer

Pancreatic Adenocarcinoma | Stage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer

United States
National Cancer Institute (NCI)

Completed

Alvocidib and Oxaliplatin With or Without Fluorouracil and Leucovorin Calcium in Treating Patients With Relapsed or Refractory Germ Cell Tumors

Stage IV Ovarian Germ Cell Tumor | Recurrent Ovarian Germ Cell Tumor | Stage III Testicular Cancer | Recurrent Malignant Testicular Germ Cell Tumor | Recurrent Extragonadal Seminoma | Recurrent Malignant Extragonadal Germ Cell Tumor | Recurrent Malignant Extragonadal Non-Seminomatous Germ Cell... and other conditions

United States
SWOG Cancer Research Network
National Cancer Institute (NCI)

Recruiting

Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers

Metastatic Small Intestinal Adenocarcinoma | Stage III Small Intestinal Adenocarcinoma AJCC v8 | Stage IIIA Small Intestinal Adenocarcinoma AJCC v8 | Stage IIIB Small Intestinal Adenocarcinoma AJCC v8 | Stage IV Small Intestinal Adenocarcinoma AJCC v8

United States
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Active, not recruiting

Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread

Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Adenocarcinoma

United States
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

Preoperative Hypofractionated Radiotherapy With FOLFOX for Esophageal or Gastroesophageal Junction Adenocarcinoma (PHOX)

Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage I Esophageal Adenocarcinoma AJCC v8 | Clinical Stage II Esophageal Adenocarcinoma AJCC v8 | Clinical Stage III Esophageal Adenocarcinoma AJCC v8 | Clinical Stage II Gastroesophageal Junction Adenocarcinoma... and other conditions

United States

Search clinical trials for: BIIL 284 BS boli

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Equatorial Guinea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations